-- The Centers for Medicare & Medicaid Services (CMS) released its preliminary Medicare payment determinations for the PoNS Controller and Mouthpiece --
-- Public Meeting Scheduled for May 29, 2024 --
NEWTOWN, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the Centers for Medicare & Medicaid Services (CMS) posted proposed Medicare Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) fee schedule payment rates for the PoNS Controller and Mouthpiece to be discussed at the bi-annual Healthcare Common Procedure Coding System (HCPCS) Public Meeting, scheduled for May 29, 2024.
For the PoNS Mouthpiece (HCPCS code A4594), CMS based pricing on the cash pay price of $4,500, resulting in a total capped payment of $3,075.53. For the PoNS Controller (HCPCS Code A4593), CMS preliminarily set pricing by mapping reimbursement to existing code E0745, (Neuromuscular stimulator, electronic shock unit), resulting in a total capped fee of $1,206.53.
"CMS's preliminary determination of reimbursement for both the PoNS Controller and Mouthpiece is a significant win for Helius," stated Helius' President and Chief Executive Officer, Dane Andreeff. "We intend to present at the HCPCS Public Meeting on May 29, 2024 and expand on how PoNS differs, mechanistically and therapeutically, from any neuromuscular peripheral stimulation therapy. We will present arguments to support a higher reimbursement rate for the PoNS Controller using the gap filling methodology, along with advocating for reimbursing the PoNS Mouthpiece through the lump sum payment structure at a higher rate than the one established in the preliminary determination."
"Once the decision is finalized, the payment rates will be effective October 1, 2024. We believe Medicare price determination will allow us to expand reimbursement across third-party payers and give us a pathway to positive cash flow as we continue pursuing authorization for stroke in the U.S."
The preliminary payment determinations published by CMS for discussion at the Public Meeting are only proposed fee schedule rates. The Company cannot provide any assurance that these rates will be finalized and adopted in their current amounts, or at all.
— 醫療保險和醫療補助服務中心（CMS）發佈了對PonS控制員和喉舌的初步醫療保險補助金決定 —
--定於 2024 年 5 月 29 日舉行的公開會議--
賓夕法尼亞州紐敦，2024年5月6日（GLOBE NEWSWIRE）——專注於爲平衡和步態缺陷提供新型治療性神經調節方法的神經科技公司Helius Medical Technologies, Inc.（納斯達克股票代碼：HSDT）（“Helius” 或 “公司”）今天宣佈，醫療保險和醫療補助服務中心（CMS）發佈了擬議的醫療保險耐用醫療設備假肢，將在兩年一次的醫療保健通用程序編碼系統（HCPCS）公開會議上討論PonS控制器和喉舌的費用表付款標準（DMEPOS）會議定於2024年5月29日舉行。
對於PonS Mouthpiece（HCPCS代碼 A4594），CMS的定價基於4500美元的現金支付價格，因此總付款上限爲3,075.53美元。對於PonS控制器（HCPCS代碼 A4593），CMS最初通過將報銷與現有代碼 E0745（神經肌肉刺激器、電子休克裝置）對應來設定價格，因此總費用上限爲1,206.53美元。
Helius總裁兼首席執行官戴恩·安德烈夫表示：“CMS初步確定了PonS控制器和喉舌的報銷，這對Helius來說是一個重大勝利。”“我們打算在2024年5月29日的HCPCS公開會議上發表演講，並詳細介紹PonS在機制和治療上與任何神經肌肉外周刺激療法的區別。我們將提出論據，支持使用填補缺口的方法提高PonS主計長的報銷率，同時主張通過一次性付款結構以比初步決定中規定的更高的費率向PonS的喉舌進行補償。”
“決定最終確定後，付款費率將於2024年10月1日生效。我們相信，醫療保險價格的確定將使我們能夠擴大第三方付款人的報銷範圍，並在我們繼續尋求美國中風批准的同時，爲我們提供一條通往正現金流的途徑。”
CMS發佈的供公開會議討論的初步付款決定僅是擬議的費用表費率。公司無法保證這些費率將按當前金額最終確定並採用，或者根本無法保證。
